AstraZeneca warned of “increasingly challenging market conditions” after fourth-quarter profits fell 13 per cent to $1.8bn (£905m)

The Anglo-Swedish pharmaceutical group forecast low sales growth in 2008, on a constant currency basis, due to competition from generic drugmakers and pricing pressure from the healthcare sector.